Product characteristics
Find out about the characteristics of MabThera that make it ideally suited to the treatment of non-Hodgkin's lymphoma
Molecular features
MabThera is a chimeric antibody targeted against the B-cell-specific CD20 antigen
Learn more about the molecular features of MabThera
Clinical pharmacokinetics of MabThera
Higher serum concentrations of MabThera have been shown to correlate with response
Clinical pharmacokinetics of MabThera
CD20: an ideal target antigen
CD20 is expressed on most NHL malignant B-cells, but not on stem cells or mature plasma cells
CD20: an ideal target antigenYour feedback is valuable to MabThera
Brief prescribing information
Download the Brief Prescribing Information for MabThera.
NHL subtypes
The WHO/REAL classification system is used worldwide for differentiation of NHL subtypes.
MabThera product characteristics
Find out more about the characteristics of MabThera and how it is used in the treatment of non-Hodgkin's lymphoma.
- Disclaimer: Mabthera.com is a resource for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
- © 2010 F. Hoffmann-La Roche Ltd.